Global Smoking Cessation Market Analysis and Forecasts Preparing for the first blockbuster

Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies?

In 2007 visiongain believes the anti-smoking market to be worth $1.7 billion. This is a growth of 37% from the year before. This latest report from visiongain, Global Smoking Cessation Market Analysis & Forecasts - preparing for the first blockbuster, explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The report examines key smoking cessation markets such as:

- US

- Japan

- Canada

- Germany

- France

- Italy

- Spain

- UK

- Sweden

- Australia

In this report each one of these disease areas is examined in terms of market growth and revenue. Plus we examine how current and new drug treatments will take hold in each market, plus which companies will succeed in each market.

According to the findings of this new report, visiongain reveals that the nicotine vaccine market will generate over $1 billion plus that Pfizer's nicotinic receptor will be the markets first blockbuster drug.

Can any of these drugs compete with the OTC market leaders? How will GSK's Zyban be effected with direct competition from Chantix/ Champix? However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC smoking cessation drugs by product type. The study also assess' the challenges faced by anti-smoking companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report:

This report features tables, graphs and charts, news, insights, the latest developments and an in depth survey of the anti-smoking market with up-to-date analysis. This report is a vital addition to gaining an understanding of this profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

With unmet medical needs this market and a growing user base, by how much will the market grow? Enough for some products to begin to lose revenue? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ophthalmic pharmaceutical market.

Key questions that this report answers are:

* What R&D opportunities exist for ‘new comers’?

* Which current or future therapies will drive the smoking cessation market?

* With 17 new drugs with new targets - which will succeed?

* The key companies involved in the market and their analysis?

* What are the current and future blockbusters within the smoking cessation industry?

Unique benefits to you when you order this report:

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 04/07/07

Pages: 151

PDF Format
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5,998.00
Company-wide Intranet Licence $9,998.00